Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2007 Jul 11;13(2):206–223. doi: 10.1111/j.1527-3458.2007.00012.x

Characterization of the Potent 5‐HT1A /B Receptor Antagonist and Serotonin Reuptake Inhibitor SB‐649915: Preclinical Evidence for Hastened Onset of Antidepressant/Anxiolytic Efficacy

Jeannette M Watson 1, Lee A Dawson 1
PMCID: PMC6726354  PMID: 17627673

ABSTRACT

An increase in brain serotonin (5‐HT) levels is thought to be a key mechanism of action responsible for generating antidepressant efficacy. It has been proven that selective serotonin reuptake inhibitors are effective antidepressants, but the delay to therapeutic onset of these agents is thought to be due to the time required for 5‐HT1A, and possibly 5‐HT1B, autoreceptors to desensitize. Therefore, an agent incorporating 5‐HT reuptake inhibition coupled with 5‐HT1A and/or 5‐HT1B autoreceptor antagonism may provide a fast‐acting clinical agent. The current studies review the profile of SB‐649915 (6‐[(1‐{2‐[(2‐methylquinolin‐5‐yl)oxy]ethyl}piperidin‐4‐yl)methyl]‐2H‐1,4‐benzoxazin‐3(4H)‐one), a novel compound with high affinity for human (h) 5‐HT1A and 5‐HT1B receptors (pKi values of 8.6 and 8.0, respectively) as well as the (h) 5‐HT transporter (SERT) (pKi value of 9.3). SB‐649915 behaved as an antagonist at both 5‐HT1A and 5‐HT1B receptors in vitro and in vivo, reversing 5‐HT, (+)8‐hydroxy‐2‐(di‐n‐propylamino) tetralin (8‐OH‐DPAT) and SKF99101‐induced functional/behavioral responses. Furthermore, it inhibited [3H]5‐HT reuptake in rat cortical synaptosomes, in vitro and ex vivo. In electrophysiological studies SB‐649915 had no effect on rat dorsal raphe neuronal cell firing per se, but reversed 8‐OH‐DPAT–induced inhibition of firing both in vitro and in vivo. In addition, in a microdialysis study, it produced an acute increase in extracellular 5‐HT in forebrain structures of the rat. Finally, SB‐649915 demonstrated acute anxiolytic activity in both rodent and non‐human primate and reduced the latency to onset of anxiolytic behavior, compared to paroxetine, in the rat social interaction paradigm. In summary, SB‐649915 is a novel, potent 5‐HT1A/1B autoreceptor antagonist, and 5‐HT reuptake inhibitor. This particular pharmacological profile provides a novel mechanism that could offer fast‐acting antidepressant activity.

Keywords: Antagonist, Autoreceptor, Dorsal raphe neuron (DRN), Electrophysiology, 5‐HT reuptake, 5‐HT1A receptor, 5‐HT1B receptor, Microdialysis, SB‐649915

Full Text

The Full Text of this article is available as a PDF (624.1 KB).

Conflict of interest. The authors are employed by GlaxoSmith Kline, the developer of SB‐649915.

REFERENCES

  1. Adham N, Romanienko P, Hartig P, Weinshank RL, Brancheck TA (1992) The rat 5‐hydroxytryptamine1B receptor is the species homologue of the human 5‐HT1D β receptor. Mol Pharmacol 41:1‐7. [PubMed] [Google Scholar]
  2. Artigas F, Celada P, Laruelle M, Adell A (2001) How does pindolol improve antidepressant action? TIPS 22:224‐228. [DOI] [PubMed] [Google Scholar]
  3. Artigas F, Perez V, Alvarez E (1994) Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 51:48‐51. [DOI] [PubMed] [Google Scholar]
  4. Artigas F, Romero L, De Montigny C, Blier P (1996) Acceleration of the effect of selected antidepressant drugs in major depression by 5‐HT1A antagonists. TINS 19:378‐383. [DOI] [PubMed] [Google Scholar]
  5. Atkinson PJ, Bromidge SM, Duxon MS, Gaster LM, Hadley MS, Hammond B, Johnson CN, Middlemiss DN, North SE, Price GW, et al. (2005) 3,4‐Dihydro‐2H‐benzoxazinones are 5‐HT1A receptor antagonists with potent 5‐HT reuptake inhibitory activity. Bioorg Med Chem Lett 15:737‐741. [DOI] [PubMed] [Google Scholar]
  6. Bel N, Artigas F (1993) Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 15:243‐245. [DOI] [PubMed] [Google Scholar]
  7. Berton O, Durand M, Aguerre S, Mormede P, Chaouloff F (1999) Behavioral, neuroendocrine and serotonergic consequences of single social defeat and repeated fluoxetine pretreatment in the Lewis rat strain. Neuroscience 92:327‐341. [DOI] [PubMed] [Google Scholar]
  8. Beyer CE, Boikess SR, Luo B, Dawson LA (2002) Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: An in vivo microdialysis study. J Psychopharmacol 16:297‐304. [DOI] [PubMed] [Google Scholar]
  9. Bianchi M, Hagan JJ, Heidbreder CA (2005) Neuronal plasticity, stress and depression: Involvement of the cytoskeletal microtubular system? Curr Drug Targets CNS Neurol Disord 4:597‐611. [DOI] [PubMed] [Google Scholar]
  10. Blier P, Bergeron R (1995) Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 15:217‐222. [DOI] [PubMed] [Google Scholar]
  11. Blier P, Bouchard C (1994) Modulation of 5‐HT release in the guinea‐pig brain following long term administration of antidepressant drugs. Br J Pharmacol 113:485‐495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Blier P, DeMontigny C (1983) Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat. J Neurosci 3:1270‐1278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Blier P, Chaput Y, DeMontigny C (1988) Long‐term 5‐HT uptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5‐HT autoreceptors: An electrophysiologic study in the rat brain. Arch Pharmacol 337:246‐254. [DOI] [PubMed] [Google Scholar]
  14. Blier P, De Montigny C, Chaput Y (1987) Modifications of the serotonin system by antidepressant treatments: Implications for the therapeutic response in major depression. J Clin Psychopharmacol 7:24‐35. [PubMed] [Google Scholar]
  15. Boulenguez P, Rawlins JN, Chauveau J, Joseph MH, Mitchell SN, Gray JA (1996) Modulation of dopamine release in the nucleus accumbens by 5‐HT1B agonists: Involvement of the hippocampo‐accumbens pathway. Neuropharmacology 35(11):1521‐1529. [DOI] [PubMed] [Google Scholar]
  16. Casanovas JM, Hervas I, Artigas F (1999) Postsynaptic 5‐HT1A receptors control 5‐HT release in the rat medial prefrontal cortex. Neuroreport 10:1441‐1445. [DOI] [PubMed] [Google Scholar]
  17. Celine F, Ouissame MF, Nasser H (2006) Long‐term adaptive changes induced by serotonergic antidepressant drugs. Expert Rev Neurother 6:235‐245. [DOI] [PubMed] [Google Scholar]
  18. Chaput Y, De Montigny C, Blier P (1986) Effects of a selective 5‐HT reuptake blocker, citalopram, on the sensitivity of 5‐HT autoreceptors: Electrophysiological studies in the rat brain. Naunyn Schmiedeberg's Arch Pharmacol 333:342‐348. [DOI] [PubMed] [Google Scholar]
  19. Clifford EM, Gartside SE, Umbers V, Cowen PJ, Hajos M, Sharp T (1998) Electrophysiological and neurochemical evidence that pindolol has agonist properties at the 5‐HT1A autoreceptor in vivo . Br J Pharmacol 124:206‐212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Consolo S, Arnaboldi S, Ramponi S, Nannini L, Ladinsky H, Baldi G (1996) Endogenous serotonin facilitates in vivo acetylcholine release in rat frontal cortex through 5‐HT1B receptors. J Pharmacol Exp Ther 277:823‐830. [PubMed] [Google Scholar]
  21. Corradetti R, Laaris N, Hanoun N, LePoul E, Hamon M, Lanfumey L (1998) Antagonist properties of (‐)‐pindolol and WAY100635 at somatodendritic and postsynaptic 5‐HT1A receptors in the rat brain. Br J Pharmacol 123:449‐462. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Costall B, Domeney AM, Gerrard PA, Kelly ME, Naylor RJ (1988a) Zaclopride: Anxiolytic profile in rodent and primate models of anxiety. J Pharm Pharmacol 40:302‐305. [DOI] [PubMed] [Google Scholar]
  23. Costall B, Domeney AM, Gerrard PA, Naylor RJ (1988b). A primate model for the assessment of anxiolytic drug action. Br J Pharmacol 95( suppl ):670P. [Google Scholar]
  24. Davidson C, Stamford JA (1995) Evidence that 5‐HT release in rat dorsal raphe nucleus is controlled by 5‐HT1A, 5‐HT1B and 5‐HT1D autoreceptors. Br J Pharmacol 114:1107‐1109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Dawson LA, Hughes ZA, Starr KR, Storey JD, Bettelini L, Bacchi F, Arban R, Poffe A, Melotto S, Hagan JJ, et al. (2006) Characterisation of the selective 5‐HT1B receptor antagonist SB‐616234‐A (1‐[6‐(cis‐3,5‐dimethylpiperazin‐1‐yl)‐2,3‐dihydro‐5‐methoxyindol‐1‐yl]‐1‐[2′‐methyl‐4′‐(5‐methyl‐1,2,4‐oxadiazol‐3‐yl)biphenyl‐4‐yl]methanone hydrochloride): In vivo neurochemical and behavioural evidence of anxiolytic activity. Neuropharmacol 50:975‐983. [DOI] [PubMed] [Google Scholar]
  26. Dawson LA, Nguyen HQ (1998) Effects of the 5‐HT1A receptor antagonists on fluoxetine‐induced changes in serotonin in rat frontal cortex. Eur J Pharmacol 345:41‐46. [DOI] [PubMed] [Google Scholar]
  27. Dawson LA, Nguyen HQ, Smith DI, Schechter LE (2000) Effects of chronic fluoxetine treatment, in the presence and absence (±) pindolol: A microdialysis study. Br J Pharmacol 130:797‐804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Dawson LA, Nguyen HQ, Smith DI, Schechter LE (2002) Effect of chronic fluoxetine and WAY‐100635 treatment on serotonergic neurotransmission in the frontal cortex. J Psychopharmacol 16:145‐152. [DOI] [PubMed] [Google Scholar]
  29. Dekeyne A, Brocco M, Adhumeau A, Gobert A, Millan MJ (2000) The selective serotonin 5‐HT1A receptor ligand, S15535, displays anxiolytic‐like effects in the social interaction and Vogel models and suppresses dialysate levels of 5‐HT in the dorsal hippocampus of freely‐moving rats. A comparison with other anxiolytic agents. Psychopharmacologia 152:55‐66. [DOI] [PubMed] [Google Scholar]
  30. Delgado JMR, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR (1990) Serotonin function and the mechanism of antidepressant action: Reversal of antidepressant‐induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 47:411‐418. [DOI] [PubMed] [Google Scholar]
  31. Duxon MS, Starr KR, Upton N (2000) Latency to paroxetine‐induced anxiolysis in the rat is reduced by co‐adminstration of the 5‐HT1A receptor antagonist WAY100635. Br J Pharmacol 130:1713‐1719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Forster EA, Cliffe IA, Bill DJ, Dover GM, Jones D, Reilly Y, Fletcher A (1995) A pharmacological profile of the selective silent 5‐HT1A receptor antagonist, WAY‐100635. Eur J Pharmacol 281:81‐88. [DOI] [PubMed] [Google Scholar]
  33. Gardner CR (1985) Distress vocalization in rat pups a simple screening method for anxiolytic drugs. J Pharmacol Meths 14:181‐187. [DOI] [PubMed] [Google Scholar]
  34. Gartside SE, Umbers V, Hajos M, Sharp T (1995) Interaction between a selective 5‐HT1A receptor antagonist and an SSRI in vivo: Effects on 5‐HT cell firing and extracellular 5‐HT. Br J Pharmacol 115:1064‐1070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Gobbi M, Crespi D, Foddi MC, Fracasso C, Mancini L, Parotti L, Mennini T (1997) Effects of chronic treatment with fluoxetine and citalopram on 5‐HT uptake, 5‐HT1B autoreceptors, 5‐HT3 and 5‐HT4 receptors in rats. Naunyn Schmiedeberg's Arch Pharmacol 356:22‐28. [DOI] [PubMed] [Google Scholar]
  36. Gobert A, Dekeyne A, Millan MJ (2000) The ability of WAY100635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co‐administration of SB224289, but not BRL15572. Neuropharmacology 39:1608‐1616. [DOI] [PubMed] [Google Scholar]
  37. Gobert A, Rivet JM, Cistarelli L, Millan MJ (1997) Potentiation of the fluoxetine‐induced increase in dialysate levels of serotonin (5‐HT) in the frontal cortex of freely moving rats by combined blockade of 5‐HT1A and 5‐HT1B receptors with WAY 100635 and GR 127935. J Neurochem 68:1159‐1163. [DOI] [PubMed] [Google Scholar]
  38. Griebel G, Blanchard DC, Agnes RS, Blanchard RJ (1995) Differential modulation of antipredator defensive behavior in Swiss‐Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology 120:57‐66. [DOI] [PubMed] [Google Scholar]
  39. Griebel G, Moreau JL, Jenck F, Misslin R, Martin JR (1994) Acute and chronic treatment with 5‐HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology 113:463‐470. [DOI] [PubMed] [Google Scholar]
  40. Hajos M, Gartside SE, Villa AE, Sharp T (1995) Evidence for a repetitive (burst) firing pattern in a sub‐population of 5‐hydroxytryptamine neurons in the dorsal and median raphe nuclei of the rat. Neuroscience 69:189‐197. [DOI] [PubMed] [Google Scholar]
  41. Hajos‐Korcsok E, McQuade R, Sharp T (1999) Influence of 5‐HT1A receptors on central noradrenergic activity: Microdialysis studies using (±)‐MDL 73005EF and its enantiomers. Neuropharmacology 38:299‐306. [DOI] [PubMed] [Google Scholar]
  42. Hensler JG (2002) Differential regulation of 5‐HT1A receptor‐G protein interactions in brain following chronic antidepressant administration. Neuropsychopharmacol 26:565‐573. [DOI] [PubMed] [Google Scholar]
  43. Hervas I, Vilaro MT, Romero L, Scorza CM, Mengod G, ARTIGAS F (2001) Desensitization of 5‐HT1A autoreceptors by a low chronic fluoxetine dose: Effect of the concurrent administration of WAY‐100635. Neuropsychopharmacol 24:11‐20. [DOI] [PubMed] [Google Scholar]
  44. Hjorth S, Bengtsson HJ, Kullberg A, Carlzon D, Peilot H, Auerbach SB (2000) Serotonin autoreceptor function and antidepressant drug action. J Psychopharmacol 14:1777‐1785. [DOI] [PubMed] [Google Scholar]
  45. Hogg S, Dalvi A (2004) Acceleration of onset of action in schedule‐induced polydipsia: Combinations of SSRI and 5‐HT1A and 5‐HT1B receptor antagonists. Pharmacol Biochem Behav 77:69‐75. [DOI] [PubMed] [Google Scholar]
  46. Hudzik TJ, Yanek M, Porrey T, Evenden J, Paronis C, Mastrangelo M, Ryan C, Ross S, Stenfors (2003) Behavioral pharmacology of AR‐A000002, a novel, selective 5‐hydroxytryptamine1B antagonist. J Pharmacol Exp Ther 304:1072‐1084. [DOI] [PubMed] [Google Scholar]
  47. Hughes ZA, Scott C, Starr KR, Newson M, Sharp T, Watson JM, Hagan JJ & Dawson LA (2007) Simultaneous blockade of 5‐HT1A receptors and the 5‐HT transporter results in acute increases in extracellular 5‐HT in both rats and guinea pigs: In vivo characterization of the novel 5‐HT1A /B receptor/5‐HT transport inhibitor SB‐649915‐B. Psychopharmacol (Published on‐line; doi: DOI: 10.1007/500213-006-0691-x). [DOI] [PubMed] [Google Scholar]
  48. Iyer RN, Bradberry CW (1996) Serotonin‐mediated increase in prefrontal cortex dopamine release: Pharmacological characterization. J Pharmacol Exp Ther 277:40‐47. [PubMed] [Google Scholar]
  49. Koyama T, Nakajima Y, Fujii T, Kawashima K (1999) Enhancement of cortical and hippocampal cholinergic neurotransmission through 5‐HT1A receptor‐mediated pathways by BAY x 3702 in freely moving rats. Neurosc Lett 265:333‐336. [DOI] [PubMed] [Google Scholar]
  50. Kreiss DS, Lucki I (1995) Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5‐hydroxytryptamine measured in vivo . J Pharmacol Exp Ther 274:866‐876. [PubMed] [Google Scholar]
  51. Le Poul E, Laaris N, Doucet E, Laporte A, Hamon M, Lanfumey L (1995) Early desensitization of somato‐dendritic 5‐HT1A autoreceptors in rats treated with fluoxetine or paroxetine. Naunyn-Schmeideberg's Arch Pharmacol 352:141‐148. [DOI] [PubMed] [Google Scholar]
  52. Lightowler S, Kennett GA, Williamson IJ, Blackburn TP, Tulloch IF (1994) Anxiolytic‐like effect of paroxetine in a rat social interaction test. Pharmacol Biochem Behav 49:281‐285. [DOI] [PubMed] [Google Scholar]
  53. Malagie I, Trillat AC, Jacquot C, Gardier AM (1995) Effects of acute fluoxetine on extracellular serotonin levels in the raphe: An in vivo microdialysis study. Eur J Pharmacol 286:213‐217. [DOI] [PubMed] [Google Scholar]
  54. Marcoli M, Maura G, Munari C, Ruelle A, Raiteri M (1999) Pharmacological diversity between native human 5‐HT1B and 5‐HT1D receptors sited on different neurons and involved in different functions. Br J Pharmacol 126:607‐612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. McAskill R, Taylor D (1998) Pindolol augmentation of antidepressant therapy. Br J Psychiatry 173:203‐208. [DOI] [PubMed] [Google Scholar]
  56. Middlemiss DN, Gothert M, Schlicker E, Scott CM, Selkirk JV, Watson J, Gaster LM, Wyman P, Riley G, Price GW (1999) SB‐236057, a selective 5‐HT1B receptor inverse agonist, blocks the 5‐HT human terminal autoreceptor. Eur J Pharmacol 375:359‐365. [DOI] [PubMed] [Google Scholar]
  57. Nakai K, Fujii T, Fujimoto K, Suzuki T, Kawashima K (1998) Effect of WAY‐100135 on the hippocampal acetylcholine release potentiated by 8‐OH‐DPAT, a serotonin1A receptor agonist, in normal and p‐chlorophenylalanine‐treated rats as measured by in vivo microdialysis. Neurosci Res 31:23‐29. [DOI] [PubMed] [Google Scholar]
  58. Newman ME, Shalom G, Ran A, Gur E, Van De Kar LD (2004) Chronic fluoxetine‐induced desensitization of 5‐HT1A and 5‐HT1B autoreceptors: Regional differences and effects of WAY‐100635. Eur J Pharmacol 486:25‐30. [DOI] [PubMed] [Google Scholar]
  59. Nomikos GG, Arborelius L, Hook BB, Hacksell U, Svensson TH (1996) The 5‐HT1A receptor antagonist (S)‐UH‐301 decreases dopamine release in the rat nucleus accumbens and striatum. J Neural Transmission – General Section 103:541‐554. [DOI] [PubMed] [Google Scholar]
  60. Oksenberg D, Marsters SA, O'Dowd BF, Jin H, Havlik S, Peroutka SJ, Ashkenazi A (1992) A single amino‐acid difference confers major pharmacological variation between human and rodent 5‐HT1B receptors. Nature 360:161‐163. [DOI] [PubMed] [Google Scholar]
  61. Olivier B, Molewijk HE, Van Der Heydden JA, Van Oorschot R, Ronken E, Mos J, Miczek KA (1998) Ultrasonic vocalizations in rat pups: Effects of serotonergic ligands. Neurosci Biobehav Rev 23:215–227. [DOI] [PubMed] [Google Scholar]
  62. Porsolt D, Bertin A, Jalfre M (1977a) Behavioural despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327‐336. [PubMed] [Google Scholar]
  63. Porsolt RD, Le Pichon M, Jalfre M (1977b). Depression: A new animal model sensitive to antidepressant treatments. Nature 266:730‐732. [DOI] [PubMed] [Google Scholar]
  64. Raap DK, Evans S, Garcia F, Li Q, Muma NA, Wolf WA, Battaglia G, Van Der Kar LD (1999) Daily injections of fluoxetine induce dose‐dependent desensitization of hypothalamic 5‐HT1A receptors: Reductions in neuroendocrine responses to 8‐OH‐DPAT and in levels of Gz and Gi proteins. J Pharmacol Exp Ther 288:98‐106. [PubMed] [Google Scholar]
  65. Rabiner EA, Bhagwagar Z, Gunn RN, Sargent PA, Bench CJ, Cowen PJ, Grasby PM (2001) Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am. J Psychiatry 158:2080‐2082. [DOI] [PubMed] [Google Scholar]
  66. Roberts C, Boyd DF, Middlemiss DN, Routledge C (1999) Enhancement of 5‐HT1B and 5‐HT1D receptor antagonist effects on extracellular 5‐HT levels in the guinea‐pig brain following concurrent 5‐HT1A or 5‐HT re‐uptake site blockade. Neuropharmacology 38:1409‐1419. [DOI] [PubMed] [Google Scholar]
  67. Roberts C, Hatcher P, Hagan JJ, Austin NE, Jeffrey P, Wyman P, Gaster LM, Routledge C, Middlemiss DN (2000) The effect of SB‐236057‐A, a selective 5‐HT1B receptor inverse agonist, on in vivo extracellular 5‐HT levels in the freely‐moving guinea pig. Naunyn Schmiedeberg's Arch Pharmacol 362:177‐183. [DOI] [PubMed] [Google Scholar]
  68. Roberts C, Price GW (2001) Interaction of serotonin autoreceptor antagonists in the rat dorsal raphe nucleus: An in vitro fast cyclic voltammetry study. Neurosci Lett 300:45‐48. [DOI] [PubMed] [Google Scholar]
  69. Roberts C, Watson J, Burton M, Price GW, Jones BJ (1996) Functional characterization of the 5‐HT terminal autoreceptor in the guinea‐pig brain cortex. Br J Pharmacol 117:384‐388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Romero L, Artigas F (1997) Preferential potentiation of the effects of serotonin uptake inhibitors by 5‐HT1A receptor antagonists in the dorsal raphe pathway: Role of somatodendritic autoreceptors. J Neurochem 68:2593‐2603. [DOI] [PubMed] [Google Scholar]
  71. Schechter LE, Mcgonigle P, Barrett JE (1999) Serotonergic antidepressants: Current and future perspectives. Curr Opin Cent Periph Nerv Sys Investig Drugs 1:432‐447. [Google Scholar]
  72. Scott C, Soffin EM, Hill M, Atkinson PJ, Langmead CJ, Wren PB, Faedo S, Gordon LJ, Price GW, Bromidge S, Watson J et al. (2006) SB‐649915, a novel, potent 5‐HT1A and 5‐HT1B autoreceptor antagonist and 5‐HT re‐uptake inhibitor in native tissue. Eur J Pharmacol 536:54‐61. [DOI] [PubMed] [Google Scholar]
  73. Scott C, Watson J, Middlemiss DN, Price GW (2000) 5‐HT1B receptor agonist: Antagonist binding affinity differences as a measure of intrinsic activity. Br J Pharmacol 129:159P. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Selkirk JV, Scott C, Ho M, Burton MJ, Watson J, Gaster LM, Jones BJ, Middlemiss DN, Price GW (1998) SB‐224289—a novel selective (human) 5‐HT1B receptor antagonist with negative intrinsic activity. Br J Pharmacol 125:202‐208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Shalom G, Gur E, Van De Kar LD, Newman ME (2004) Repeated administration of the 5‐HT1B receptor antagonist SB‐224289 blocks the desensitization of 5‐HT1B autoreceptors induced by fluoxetine in rat frontal cortex. Naunyn Schmiedeberg's Arch Pharmacol 370:84‐90. [DOI] [PubMed] [Google Scholar]
  76. Sharp T, Umbers V, Gartside SE (1997) Effect of a selective 5‐HT reuptake inhibitor in combination with 5‐HT1A and 5‐HT1B receptor antagonists on extracellular 5‐HT in rat frontal cortex in vivo . Br J Pharmacol 121:941‐946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Shen C, Li H, Meller E (2002) Repeated treatment with antidepressants differentially alters 5‐HT1A agonist‐stimulated [35S]GTPγS binding in rat brain regions. Neuropharmacology 42:1031‐1038. [DOI] [PubMed] [Google Scholar]
  78. Shopsin B (1978) Enhancement of the antidepressant response to L‐tryptophan by a liver pyrrolase inhibitor: A rational treatment. Neuropsychobiology 4:188‐192. [DOI] [PubMed] [Google Scholar]
  79. Skingle M, BeattiesS DT, Scopes DIC, Starkey SJ, Connor HE, Feniuk W, Tyers MB (1996) GR127935: A potent and selective 5‐HT1D receptor antagonist. Behav Brain Res 73:157‐161. [DOI] [PubMed] [Google Scholar]
  80. Starr KR, Price GW, Watson JM, Atkinson PJ, Arban R, Melotto S, Dawson LA, Hagan JJ, Upton N, Duxon MS (2007) SB‐649915‐B, a novel 5‐HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor is anxiolytic and displays fast onset of activity in the rat high light social interaction test. Neuropsychopharmacology (online publication; doi: DOI: 10.1038/sj.npp.1301341) [DOI] [PubMed] [Google Scholar]
  81. Stean TO, Atkins AR, Heidbreder CA, Quinn LP, Trail BK, Upton N (2005) Postsynaptic 5‐HT1B receptors modulate electroshock‐induced generalised seizures in rats. Br J Pharmacol 144:628‐635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. To CT, Anheuer ZE, Bagdy G (1999) Effects of acute and chronic fluoxetine treatment of CRH‐induced anxiety. Neuroreport 25 10:553‐555. [DOI] [PubMed] [Google Scholar]
  83. To CT, Bagdy G (1999). Anxiogenic effect of central CCK administration is attenuated by chronic fluoxetine or ipsapirone treatment. Neuropharmacology 38:279‐282. [DOI] [PubMed] [Google Scholar]
  84. Watson J, Burton M, Price GW, Jones BJ, Middlemiss DN (1996) GR127935 acts as a partial agonist at recombinant human 5‐HT1D α and 5‐HT1D β receptors. Eur J Pharmacol 314:365‐372. [DOI] [PubMed] [Google Scholar]
  85. Watson J, Collin L, Ho M, Riley G, Scott C, Selkirk JV, Price GW (2000) 5‐HT1A receptor agonist‐antagonist binding affinity differences as a measure of intrinsic activity in recombinant and native tissue systems. Br J Pharmacol 130:1108‐1114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Yamada M, Yamada M, Higuchi T (2005) Antidepressant‐elicited changes in gene expression: Remodeling of neuronal circuits as a new hypothesis for drug efficacy. Prog Neuropsychopharmacol Biol Psychiatry 29:999‐1009. [DOI] [PubMed] [Google Scholar]
  87. Young SN, Smith SE, Pihl RO, Ervin FR (1985) Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology 87:173‐177. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES